Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
29 studies found for:    hemolytic anemia OR G6PD OR paroxysmal nocturnal hemoglobinuria OR thalassemias | Open Studies | NIH, U.S. Fed
Show Display Options
Rank Status Study
1 Recruiting Nonmyeloablative Peripheral Blood Mobilized Hematopoietic Precursor Cell Transplantation for Sickle Cell Disease and Beta-thalassemia in People With Higher Risk of Transplant Failure
Conditions: Sickle Cell Disease;   Thalassemia;   Stem Cell Transplantation;   Graft vs Host Disease
Interventions: Drug: Alemtuzumab;   Drug: Sirolimus;   Drug: Cyclophosphamide;   Drug: Pentostatin;   Drug: Radiotherapy
2 Not yet recruiting Screening for Alpha Thalassemia in Healthy Volunteers
Condition: Alpha Thalassemia
Intervention:
3 Recruiting Improving the Results of Bone Marrow Transplantation for Patients With Severe Congenital Anemias
Conditions: Congenital Hemolytic Anemia;   Diamond-Blackfan Anemia
Interventions: Procedure: Radiotherapy;   Drug: Alemtuzumab (Campath );   Drug: Sirolimus (Rapamune )
4 Recruiting Secondary Pulmonary Hypertension in Adults With Sickle Cell Anemia
Conditions: Pulmonary Hypertension;   Sickle Cell Anemia;   Sickle Cell Disease
Intervention:
5 Recruiting Bone Marrow for Hemoglobinopathy Research
Conditions: Sickle Cell Anemia;   Thalassemia
Intervention:
6 Recruiting Massive Iron Deposit Assessment
Conditions: Iron Overload;   Excessive Body Iron Burden
Interventions: Device: R2*-UTE;   Device: R2*-GRE;   Procedure: Liver biopsy
7 Recruiting Preventing Sickle Cell Kidney Disease
Conditions: Anemia, Sickle Cell;   Sickle Cell Disease;   Kidney Disease;   Hypertension;   Proteinuria
Intervention: Drug: Losartan
8 Recruiting Natural History of Sickle Cell Disease
Condition: Sickle Cell Disease
Intervention:
9 Recruiting A Prospective Trial to Assess Cost and Clinical Outcomes of a Clinical Pharmacogenomic Program
Condition: Adverse Drug Reaction
Intervention: Device: Pharmacogenetic Intervention Arm (pharmacogenetic testing)
10 Recruiting The Role of Endothelin-1 in Sickle Cell Disease
Condition: Sickle Cell Anemia
Interventions: Drug: Ambrisentan;   Drug: Placebo
11 Recruiting Allogeneic Hematopoietic Stem Cell Transplantation for Severe Aplastic Anemia and Other Bone Marrow Failure Syndromes Using G-CSF Mobilized CD34+ Selected Hematopoietic Precursor Cells Co-Infused With a Reduced Dose of Non-Mobilized Donor T-cells
Conditions: Severe Aplastic Anemia;   MDS (Myelodysplastic Syndrome)
Interventions: Device: Miltenyi CD34 Reagent System;   Other: Donor derived G-CSF mobilized PBC
12 Recruiting Fludarabine Phosphate and Total Body Irradiation Followed by a Donor Peripheral Stem Cell Transplant in Treating Patients With Myelodysplastic Syndromes or Myeloproliferative Disorders
Conditions: Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative;   Chronic Myelomonocytic Leukemia;   de Novo Myelodysplastic Syndrome;   Essential Thrombocythemia;   Myeloproliferative Neoplasm;   Paroxysmal Nocturnal Hemoglobinuria;   Polycythemia Vera;   Polycythemia Vera, Post-Polycythemic Myelofibrosis Phase;   Primary Myelofibrosis;   Refractory Anemia;   Refractory Anemia With Excess Blasts;   Refractory Anemia With Ring Sideroblasts;   Refractory Cytopenia With Multilineage Dysplasia;   Refractory Cytopenia With Multilineage Dysplasia and Ring Sideroblasts
Interventions: Drug: Cyclosporine;   Drug: Fludarabine Phosphate;   Other: Laboratory Biomarker Analysis;   Drug: Mycophenolate Mofetil;   Procedure: Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation;   Procedure: Peripheral Blood Stem Cell Transplantation;   Radiation: Total-Body Irradiation
13 Recruiting Specialized Blood Cell Transplants for Cancers of the Blood and Bone Marrow
Conditions: Hematologic Disease;   Lymphoma;   Multiple Myeloma;   Myelodysplastic Syndrome;   Myeloproliferative Disorder
Intervention: Procedure: Stem cell transplantation
14 Recruiting Treosulfan and Fludarabine Phosphate Before Donor Stem Cell Transplant in Treating Patients With Nonmalignant Inherited Disorders
Condition: Non-Malignant
Interventions: Procedure: Allogeneic Bone Marrow Transplantation;   Biological: Anti-Thymocyte Globulin;   Drug: Cyclosporine;   Drug: Fludarabine Phosphate;   Other: Laboratory Biomarker Analysis;   Drug: Methotrexate;   Drug: Mycophenolate Mofetil;   Procedure: Peripheral Blood Stem Cell Transplantation;   Drug: Tacrolimus;   Radiation: Total-Body Irradiation;   Drug: Treosulfan;   Procedure: Umbilical Cord Blood Transplantation
15 Recruiting Clinical and Laboratory Investigation of Humans With Informative Iron or Erythroid Phenotypes
Conditions: Hemoglobinopathies;   Hemolysis;   Iron Deficiency and Overload;   Anemias
Intervention:
16 Recruiting Longitudinal Changes in Exercise Capacity in Children and Young Adults With Sickle Cell Anemia
Condition: Sickle Cell Anemia
Intervention:
17 Recruiting Fludarabine, Cyclophosphamide, and Total-Body Irradiation Followed By Donor Bone Marrow Transplant in Treating Patients With Sickle Cell Anemia and Other Blood Disorders
Condition: Sickle Cell Disease
Interventions: Drug: cyclophosphamide;   Drug: fludarabine phosphate;   Drug: mycophenolate mofetil;   Drug: Sirolimus;   Procedure: Allogeneic bone marrow transplantation;   Radiation: total-body irradiation;   Drug: Levetiracetam
18 Recruiting Cancer in Inherited Bone Marrow Failure Syndromes
Conditions: Aplastic Anemia;   Head and Neck Neoplasms;   Bone Marrow Failure
Intervention:
19 Recruiting Screening for Subjects to Participate in Studies of Blood Disorders
Conditions: Bone Marrow Transplant;   Sickle Cell Disease;   G-CSF
Intervention:
20 Recruiting A Phase II Trial of Regadenoson in Sickle Cell Anemia
Condition: Sickle Cell Anemia
Interventions: Drug: Regadenoson;   Drug: Placebo

   Previous Page Studies Shown (1-20) Next Page (21-29) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.